426 related articles for article (PubMed ID: 38496036)
1. Engineering customized nanovaccines for enhanced cancer immunotherapy.
Guo J; Liu C; Qi Z; Qiu T; Zhang J; Yang H
Bioact Mater; 2024 Jun; 36():330-357. PubMed ID: 38496036
[TBL] [Abstract][Full Text] [Related]
2. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
3. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
4. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.
Li Y; Li S; Jiang Z; Tan K; Meng Y; Zhang D; Ma X
J Nanobiotechnology; 2023 Jul; 21(1):212. PubMed ID: 37415161
[TBL] [Abstract][Full Text] [Related]
5. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
6. Antigen Self-Presented Personalized Nanovaccines Boost the Immunotherapy of Highly Invasive and Metastatic Tumors.
Wang T; Han M; Han Y; Jiang Z; Zheng Q; Zhang H; Li Z
ACS Nano; 2024 Feb; 18(8):6333-6347. PubMed ID: 38349234
[TBL] [Abstract][Full Text] [Related]
7. Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.
He A; Li X; Dai Z; Li Q; Zhang Y; Ding M; Wen ZF; Mou Y; Dong H
J Nanobiotechnology; 2023 Jul; 21(1):236. PubMed ID: 37482608
[TBL] [Abstract][Full Text] [Related]
8. Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting.
Achmad H; Saleh Ibrahim Y; Mohammed Al-Taee M; Gabr GA; Waheed Riaz M; Hamoud Alshahrani S; Alexis Ramírez-Coronel A; Turki Jalil A; Setia Budi H; Sawitri W; Elena Stanislavovna M; Gupta J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109434. PubMed ID: 36402068
[TBL] [Abstract][Full Text] [Related]
9. Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
Chen J; Fang H; Hu Y; Wu J; Zhang S; Feng Y; Lin L; Tian H; Chen X
Bioact Mater; 2022 Jan; 7():167-180. PubMed ID: 34466725
[TBL] [Abstract][Full Text] [Related]
10. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
[TBL] [Abstract][Full Text] [Related]
12. Nanobiomaterial-based vaccination immunotherapy of cancer.
Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
[TBL] [Abstract][Full Text] [Related]
14. Advancements in prophylactic and therapeutic nanovaccines.
Bhardwaj P; Bhatia E; Sharma S; Ahamad N; Banerjee R
Acta Biomater; 2020 May; 108():1-21. PubMed ID: 32268235
[TBL] [Abstract][Full Text] [Related]
15. Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
Yin Q; Wang Y; Xiang Y; Xu F
Hum Vaccin Immunother; 2022 Nov; 18(6):2119020. PubMed ID: 36170662
[TBL] [Abstract][Full Text] [Related]
16. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
17. Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8
Qiu L; Valente M; Dolen Y; Jäger E; Beest MT; Zheng L; Figdor CG; Verdoes M
Small; 2018 Apr; 14(15):e1703539. PubMed ID: 29493121
[TBL] [Abstract][Full Text] [Related]
18. Nanovaccines with cell-derived components for cancer immunotherapy.
Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective.
Gholap AD; Gupta J; Kamandar P; Bhowmik DD; Rojekar S; Faiyazuddin M; Hatvate NT; Mohanto S; Ahmed MG; Subramaniyan V; Kumarasamy V
ACS Biomater Sci Eng; 2024 Jan; 10(1):271-297. PubMed ID: 38096426
[TBL] [Abstract][Full Text] [Related]
20. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
